Multiple myeloma is a hematological malignancy which results organ damage due to increased abnormal plasma cell growth in bone marrow and immunoglobulin or light chain overproduction. In myeloma treatment, it is aimed to control the disease quickly and effectively, to correct and prevent disease-related complications and to reduce the risk of premature death, with the least possible toxicity. In recent years, the survival of patients has dramatically increased with the addition of a large number of new generation agents to the treatment. Current therapies with new agents have good results related with the survival and disease-free survival but cannot prevent the recurrence of the disease. Although autologous stem cell transplantation protects its location in treatment, ıt seems to promise hope for a new generation of agents.